WAVEMAN · COMPANY

BTMD · Biote Corp.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

BTMD

Name: biote Corp. (BTMD) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

biote Corp.

PHARMA & BIOTECH · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · CIK 0001819253

C-SUITE BUYING · 1☆ WATCH

INSIDER NET · 180D

$202.2K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-2.5%

XBRL, annual

NET MARGIN

14.1%

CONVERSIONS · 180D

codes C/M, not in net · no price filed

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$202.2K over 180 days

+$202.2K over 90 days

more than 80% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

42 funds added or opened last quarter

below 58% of Pharma & Biotech

REVENUE

-2.5% year over year

below 61% of Pharma & Biotech

MARGIN

14.1% net margin

more than 85% of Pharma & Biotech

BUYBACKS

$5.9M repurchased, FY to 2026-06-30

below 77% of Pharma & Biotech

SHORT

2.6 days to cover · settled 2026-07-31

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

42 funds added or opened positions in the latest 13F quarter, of 73 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -54.8%

-54.8%12M

INSIDER BUY

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders are net buyers of their own stock.

The record shows a net $202.2K bought by insiders over 180 days, 42 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, biote Corp. insiders bought a net $202.2K of stock across 36 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Beer Marc D

Executive Chairman

BUY

2026-08-11

16,000.0

$24.8K

Beer Marc D

Executive Chairman

BUY

2026-08-10

115,950.0

$177.4K

Barrera Richard R

—

BUY

2025-05-07

11,677.0

$39.1K

Barrera Richard R

—

BUY

2025-05-06

436,037.0

$1.4M

RB Management GP LLC

—

BUY

2025-04-30

1,933.0

$6.4K

36 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 31 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

325 CAPITAL LLC

4,548,127.0 sh

$8.6M

Bandera Partners LLC

2,065,482.0 sh

$3.9M

VANGUARD CAPITAL MANAGEMENT LLC

1,102,753.0 sh

$2.1M

MILLENNIUM MANAGEMENT LLC

436,088.0 sh

$824.2K

DIMENSIONAL FUND ADVISORS LP

431,962.0 sh

$816.1K

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

North Star Micro Cap Fund

$424.0K POSITION · AS OF 2026-02-28

0.2%

Ultra-Small Company Fund

$72.0K POSITION · AS OF 2026-03-31

0.1%

Venerable US Small Cap Fund

$39.0K POSITION · AS OF 2026-03-31

0.0%

Applied Finance IVS US SMID ETF

$3.5K POSITION · AS OF 2026-03-31

0.0%

Small Company Growth Portfolio

$4.5K POSITION · AS OF 2026-03-31

0.0%

Clearwater Select Equity Fund

$72.4K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$192.2M	$197.2M	$185.4M	$165.0M
OPERATING INCOME	$35.6M	$31.6M	$28.7M	$-60.7M
NET INCOME	$27.0M	$3.2M	$3.3M	$-969.0K
EPS (DILUTED)	0.74	0.09	0.13	-0.12
OPERATING CASH FLOW	$35.2M	$45.2M	$26.9M	$-9.2M
CASH	$24.1M	$39.3M	$89.0M	$79.2M
LONG-TERM DEBT	$95.8M	$101.2M	$106.6M	$112.1M
BUYBACKS	$3.4M	$5.6M	—	—
DIVIDENDS PAID	$1.7M	$4.7M	$8.7M	$12.9M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE